Business Context and Reporting Period
This Form 8-K Current Report was filed by Conversion Labs, Inc. (not Lifemd, Inc.) on June 17, 2019, covering events occurring on June 7, 2019. The filing details significant changes to the Company's Board of Directors, including the appointment of two new directors and a change in the Chairman of the Board.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. However, it discloses specific transaction values related to director appointments:
- Securities Purchase: New director Bertrand Velge purchased 1,086,957 shares of common stock at $0.23 per share and warrants to purchase an equal number of shares at $0.28 per share.
- Compensation Agreement: New director Happy Walters entered into a consulting agreement to earn up to 5,000,000 restricted shares of common stock upon the subsidiary Conversion Labs RX, LLC reaching certain revenue milestones.
- Ownership Interest: Happy Walters retains a 22% membership interest in the Company as of the filing date.
Material Changes
The primary material changes reported are governance-related:
- Board Appointments: Mr. Happy Walters and Mr. Bertrand Velge were appointed to the Board of Directors, effective June 10, 2019.
- Chairman Resignation: Mr. John Strawn resigned as Chairman of the Board on June 7, 2019, though he remains a Board member.
- Chairman Appointment: Mr. Justin Schreiber, the Company's President and CEO, was appointed as the new Chairman of the Board.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclosures regarding related party transactions. Management commentary is limited to the biographical backgrounds of the new directors:
- Happy Walters: Brings extensive experience in entertainment, media, and sports representation, including founding Catalyst Sports & Media and previously leading Relativity Sports.
- Bertrand Velge: Brings over twenty years of experience in multi-disciplinary venture investing and serves as Managing Director of Graftyset, Ltd.
Investor Verification Checklist
- Verify the terms and specific revenue milestones in the "Walters Consulting Agreement" (Exhibit 10.1) to understand the conditions for the issuance of up to 5,000,000 restricted shares.
- Confirm the dilution impact of the 1,086,957 shares and warrants sold to Bertrand Velge.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for these board changes.
- Check subsequent filings for any updates on the revenue milestones for Conversion Labs RX, LLC.